1、1 0 D ec em b er 2 0 2 4Q225Financial ResultsA ug us t 7,2 0 2 5Forward-Looking StatementsStatements included in this press release that are not historical in nature are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.Gilead cautions readers that

2、 forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially.These risks and uncertainties include those relating to:Gileads ability to achieve its full year 2025 financial guidance,including as a result of the uncertainty of the amo

3、unt and timing of Veklury revenues,the impact of the Inflation Reduction Act,changes in U.S.regulatory or legislative policies,and changes in U.S.trade policies,including tariffs;Gileads ability to make progress on any of its long-term ambitions or priorities laid out in its corporate strategy;Gilea

4、ds ability to accelerate or sustain revenues for its virology,oncology and other programs;Gileads ability to realize the potential benefits of acquisitions,collaborations or licensing arrangements,including the acquisitions of MYR,and the arrangements with Arcellx,Kymera and the Global Fund;patent p

5、rotection and estimated loss of exclusivity for our products and product candidates;Gileads ability to initiate,progress or complete clinical trials within currently anticipated timeframes or at all,the possibility of unfavorable results from ongoing and additional clinical trials,including those in

6、volving Livdelzi,Trodelvy,Yescarta,Yeztugo(lenacapavir),anito-cel,bulevirtide,GS-1720,and GS-4182(such as the ASCENT-03,ASCENT-04,ASSURE,iMMagine-1,MYR301,PURPOSE 1,PURPOSE 2,WONDERS-1,and WONDERS-2 studies),and the risk that safety and efficacy data from clinical trials may not warrant further deve